Enquirer Consulting Group

Reachable Buyer Map

Prepared for Eduardo Wallach · Kura Biotech · United States · August 2026
Enzymes for sample preparation are bought by a very small number of very specific people, and the useful question is not how big the market is but how many named seats sit inside it. This map lays those out: the US lab segments that consume hydrolysis, molecular and pathogen detection chemistry, who signs inside each one, and roughly how many there are. It describes the market rather than your business, and there is nothing to buy at the end of it.
Clinical and pain management toxicology labs
The closest fit for sample preparation chemistry, because hydrolysis sits inside a validated method that gets audited rather than improvised. Switching is a validation project, not a purchase, which makes the segment slow to win and very slow to lose.
Who signs: laboratory director, technical supervisor, lead mass spectrometry scientist, quality manager, purchasing manager.
450 to 500
US businesses operating as dedicated toxicology laboratories
Forensic and publicly funded crime labs
Small, named, and unusually connected: the section supervisors in this segment sit on the same accreditation and method committees and talk to each other constantly. One validated method reference travels further here than in any other segment on this page. Buying runs through public procurement, which is slower but far more predictable.
Who signs: laboratory director, toxicology section supervisor, quality manager, and the agency purchasing officer.
320 to 350
publicly funded crime lab systems in the US, made up of roughly 400 to 430 individual labs
Hospital and health system labs
Enormous by count and much smaller by relevance, because most send confirmation work out rather than run it. The subset that brought mass spectrometry in house is the reachable part, and once a system standardizes, the decision covers every site under it at once.
Who signs: laboratory director, core lab manager, chemistry section head, supply chain and group purchasing contract manager.
8,000 to 9,000
hospital labs registered nationally; the subset running their own confirmation testing is a fraction of that
Independent reference and specialty labs
Where volume concentrates and where cost per sample is a board level number rather than a line item. These labs run their own method development teams, which means the conversation starts technical and stays technical, and the evaluation is run by scientists rather than by procurement.
Who signs: chief scientific officer, director of laboratory operations, method development lead, procurement director.
6,500 to 7,500
independent labs registered nationally, across all specialties
Genomics: core facilities and reagent manufacturers
Two very different buyers under one product line. A university core facility buys in small volume on the recommendation of a scientist, and a diagnostics or kit manufacturer buys enzymes as a raw material under supply agreements and change control. The second is a much longer sale and a much larger one, and it is bought by supply chain rather than by the bench.
Who signs: core facility director, principal investigator, and on the manufacturing side the VP of research and development, sourcing lead and supplier quality manager.
No single public register
core facilities and manufacturers sit under codes that do not separate them; this layer is identified institution by institution
Food safety and contract testing labs
The newest of the three lines and the one with the shortest sales cycle, because a food processor changing a pathogen method is not running a regulatory validation on the same scale. Accreditation is voluntary here, so the accredited names are the visible tip of a much larger unlisted population of in-house quality labs.
Who signs: laboratory manager, quality assurance director, food safety manager, technical services lead.
250 to 350
accredited food testing laboratories nationally; in-house quality labs at processors are far more numerous and not registered anywhere

Where the openings are

1
Three product lines, three unrelated buyers, one company name. Toxicology is bought by a lab director inside a validated method. Genomics is bought by a bench scientist at a core facility or by a sourcing lead at a manufacturer. Food safety is bought by quality assurance at a processor or a contract lab. In practice one channel tends to keep walking back through whichever door opened first, and the other two stay shut.
2
The trigger is the method change, not the calendar. A new instrument, a re-accreditation, a lost technical lead, a turnaround time problem, a cost per sample review. Each one reopens the reagent question, and each one is visible from outside if something is watching a few thousand labs for it. Waiting to be found means arriving after the validation has already started.
3
Distance is a distribution problem, not a credibility one. In this market a manufacturer based outside the country its buyers sit in typically reaches those labs through distribution and conference presence. Both channels work, and both reach labs that were already looking. Neither reaches the lab director who has never heard the name and has a hydrolysis problem this quarter.
4
The named seat is the whole game here. These are not companies, they are a few thousand identifiable people: lab directors, section supervisors, method development leads. That is a small enough universe to work properly by name and large enough that no one person can. It is a mechanical job, and it is the one we build, run for a fixed period, then hand over.
Built from public registries, counts banded deliberately. Lab counts describe registered facilities rather than buying organizations, so a network operating several sites appears more than once, and a single lab may hold more than one registration. Specialty is recorded as a field rather than as a category, so the toxicology-active subset of the wider lab population is smaller than the totals above. Core facilities, manufacturers and in-house quality labs are not separately enumerated and are described rather than counted.
ENQUIRER CONSULTING GROUP
enquirerconsulting.com